SUPPORT HOTLINE (888) 901-2226
Donate Now

BRIEF TITLE: Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

  • Org Study ID: PrE0807
  • Secondary ID: CA209-9DF
  • NCT ID: NCT03532451
  • NCT Alias:
  • Sponsor: PrECOG, LLC. - Other
  • Source: PrECOG, LLC.

Brief Summary

Patients with muscle-invasive bladder cancer (MIBC) who can not receive cisplatin or refuse cisplatin therapy will receive nivolumab or nivolumab/lirilumab before a planned surgical procedure called a radical cystectomy (RC) to remove the bladder. Nivolumab works by attaching to and blocking a molecule called Programmed Death-1 (PD-1). Lirilumab attaches to and blocks a group of molecules called Killer Cell Immunoglobulin-Like Receptor (KIR). PD-1 and KIR are proteins present mainly on immune system cells, and each controls part of the immune system by shutting it down. It is hoped that by binding to and inactivating these proteins, these drugs can enhance the body's ability to detect, attack and destroy cancer cells. The purpose of this research study is to see whether nivolumab alone or combination of nivolumab and lirilumab given before surgery is effective in treating people who have bladder cancer, and to examine the side effects, good and bad, associated with nivolumab and lirilumab.

Detailed Description

Bladder cancer (BC) is the 6th most common malignancy in the United States with an estimated
79,030 new cases and 16,870 deaths in 2017. It is the 4th most common cancer in men and there
are presently >500,000 BC patients alive in the US. It accounts for about 5% of all new
cancers in the US. It is also the most expensive cancer to treat from diagnosis to death.
Almost a third of BC patients present with MIBC.

This is a Phase Ib open-label clinical trial for patients that are either
cisplatin-ineligible or refuse cisplatin-based chemotherapy and have MIBC (T2-T4a, N0-N1,
M0).Neoadjuvant treatment must start within 10 weeks of transurethral resection of the most
recent transurethral resection of bladder tumor (TURBT) that showed muscularis propria

Patients must have sufficient baseline tumor tissue. Tumor tissue content for CD8+ T-cell
density assessment must be qualified as sufficient (≥ 20% tumor content in the specimen) for
analysis and must be documented by the local pathologist prior to registration.

The first 12 patients will be enrolled into Cohort 1 and treated with nivolumab before a
planned RC (Completed November 20, 2019).

In the absence of the occurrence of high rate of treatment related Adverse Events (AEs) with
nivolumab, the study will proceed with enrollment into Cohort 2 with the combination of
nivolumab/lirilumab before a planned RC.

Each group will receive a total of 2 doses (week 0 and 4) of nivolumab (Cohort 1) or
nivolumab/lirilumab (Cohort 2) therapy followed by RC with bilateral (standard or extended)
pelvic lymph node dissection (PLND).

Mandatory tumor tissue at Screening (archived tumor tissue from Transurethral Resection of
Bladder Tumor [TURBT] may be used) and at time of RC. Peripheral blood and urine samples are
also required.

Overal Status Start Date Phase Study Type
Recruiting March 22, 2019 Phase 1 Interventional

Primary Outcomes:

Primary Outcome 1 - Measure: Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE V5.0

Primary Outcome 1 - Time Frame: 30 months


  • Bladder Cancer


- Patients must have histologically confirmed MIBC (T2-T4a, N0-N1, M0 per American Joint
Commission on Cancer [AJCC]) pure or mixed histology urothelial carcinoma. Clinical
node-positive (N1) patients are eligible provided the lymph nodes (LNs) are confined
to the true pelvis and are within the planned surgical LN dissection template.

- The most recent TURBT that showed muscularis propria invasion should be within 10
weeks prior to beginning study therapy. Patients must have sufficient baseline tumor
tissue from either initial or repeat TURBTs. The local site pathologist will be asked
to estimate and record the rough approximate percentage of viable tumor in the TURBT
sample (initial or repeat TURBT with highest tumor content) to document at least 20%
viable tumor content prior to registration.

- Patients must be ineligible for cisplatin-based chemotherapy due to any of the
following below OR refused cisplatin-based chemotherapy:

- Creatinine clearance(CrCl) <60 mL/min with Easter Cooperative Oncology Group
(ECOG) Performance Status (PS) 0-1

- Creatinine clearance(CrCl) ≥ 60 mL/min with ECOG PS 2 (if patient fit for RC)

- Hearing impaired ≥ Grade 2 by CTCAE criteria

- Neuropathy ≥ Grade 2 by CTCAE criteria

- Patient refused cisplatin-based chemotherapy?

- Patients must be medically fit for TURBT and RC.

- Age ≥ 18 years.

- Ability to understand and willingness to sign Institutional Review Board
(IRB)-approved informed consent.

- Willing to provide tumor tissue, blood, and urine samples for research.

- Adequate organ function as measured by the following criteria, obtained ≤ 4 weeks
prior to registration:

- Absolute Neutrophil Count (ANC) ≥ 1000/mm³ (stable off growth factor within 4
weeks of first study drug administration)

- Platelets ≥ 100,000/mm³

- Hemoglobin ≥ 8 g/dL

- Serum Creatinine Clearance ≥ 30 mL/min using the Cockcroft-Gault formula

- Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤ 3x Upper
Limit of Normal (ULN)

- Total Bilirubin ≤ 1.5x ULN (in the absence of previously diagnosed Gilbert's

- Women must not be pregnant or breastfeeding since we do not know the effects of
nivolumab and lirilumab on the fetus or breastfeeding child.

- Sexually active women of child-bearing potential with a non-sterilized male partner
and sexually active men must agree to use 2 methods of adequate contraception
(hormonal plus barrier or 2 barrier forms) OR abstinence prior to study entry, for the
duration of study participation, and for 5 months for women and 7 months for men
following last dose of study drugs.

- Active or prior documented autoimmune disease within the past 2 years prior to
Screening or other immunosuppressive agent within 14 days of study treatment.

- Patients may not have locally advanced unresectable or metastatic urothelial carcinoma
as assessed on baseline radiographic imaging obtained within 28 days prior to study

- Patients may not have concurrent upper urinary tract (i.e. ureter, renal pelvis)
invasive urothelial carcinoma. Patients with history of non-invasive (Ta, Tis) upper
tract urothelial carcinoma that has been definitively treated with at least one
post-treatment disease assessment (i.e. cytology, biopsy, imaging) that demonstrates
no evidence of residual disease are eligible.

- Patients may not have another malignancy that could interfere with the evaluation of
safety or efficacy of the study drugs. Patients with a prior malignancy will be
allowed without study chair approval in the following circumstances:

- Not currently active and diagnosed at least 3 years prior to the date of

- Non-invasive diseases such as low risk cervical cancer or any cancer in situ.

- Localized (early stage) cancer treated with curative intent (without evidence of
recurrence and intent for further therapy), and in which no systemic chemotherapy
was indicated.(e.g. low/intermediate risk prostate cancer, etc.).

- Patients may not have received any prior immune checkpoint inhibitor (i.e. anti-KIR,
anti-PD-1, anti-PD-L1, or other).

- Patients may not have undergone major surgery (e.g. intra-thoracic, intra-abdominal or
intra-pelvic), open biopsy or significant traumatic injury or specific anti-cancer
treatment ≤ 4 weeks prior to starting study drug, or patients who have had
percutaneous biopsies or placement of vascular access device ≤ 1 week prior to
starting study drug, or who have not recovered from side effects of such procedure or

- Patients must not have clinically significant cardiac disease.

- Patients may not have chronic active liver disease or evidence of acute or chronic
Hepatitis B Virus (HBV) or Hepatitis C (HCV).

- Patients may not have known diagnosis of human immunodeficiency virus (HIV) infection.
Testing is not required in absence of clinical suspicion.

- Patients may not have known diagnosis of any condition (e.g. post-hematopoietic or
solid visceral organ transplant, pneumonitis, inflammatory bowel disease, etc.) that
requires chronic immunosuppressive therapy. Usage of non-steroidal anti-inflammatory
medications (NSAIDS) for the treatment of osteoarthritis and uric acid synthesis
inhibitors for the treatment of gout are permitted.

- Patients with any serious and/or uncontrolled concurrent medical conditions (e.g.
active or uncontrolled infection, uncontrolled diabetes) or psychiatric illness that
could, in the investigator's opinion, cause unacceptable safety risks or potentially
interfere with the completion of the treatment according to the protocol are not

- Patients may not have any live viral vaccine used for prevention of infectious
diseases within 4 weeks prior to study drug(s).

- Patients unwilling or unable to comply with the protocol.
Show More

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Official Information

Name: Petros Grivas, MD, PhD

Role: Study Chair

Affiliation: University of Washington

Overall Contact

Name: Carolyn Andrews, RN

Phone: 267-207-4070



Facility Status Contact
Moffitt Cancer Center
Tampa, Florida 33612
United States
Recruiting Gina Bellenger
Montefiore Medical Center
Bronx, New York 10461
United States
Recruiting Gina Aracena
Icahn School of Medicine at Mount Sinai
New York, New York 10029
United States
Recruiting Philip Garcia
Ohio State University Comprehensive Cancer Center
Columbus, Ohio 43210
United States
Recruiting Shireen Desai
Oregon Health & Science University
Portland, Oregon 97239
United States
Recruiting Michael Ritchie
University of TX Southwestern
Dallas, Texas 75390
United States
Recruiting Allison Beaver Beaver
University of Virginia
Charlottesville, Virginia 22903
United States
Recruiting Jennifer Drake, RN
University of Washington
Seattle, Washington 98109
United States
Recruiting Colin Sievers